Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278315 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cellectar Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02278315 is a Phase 1 study that has completed, run by Cellectar Biosciences. The registered enrollment target is 31 participants.
The verdict
NCT02278315, a Phase 1 study, has completed, sponsored by Cellectar Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
Interventions
- DRUG dexamethasone
- DRUG I-131-CLR1404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-02 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278315
The ClinicalTrials.gov registry entry for NCT02278315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT02278315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278315 about?
NCT02278315 is a clinical study titled "Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma". The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an imm...
What is the current status of trial NCT02278315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-02. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT02278315?
The interventions under investigation include: dexamethasone (DRUG), I-131-CLR1404 (DRUG).
Who is sponsoring clinical trial NCT02278315?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.